
The Development Factory
Unlocking the Potential of Process Innovation
Gary P. Pisano(Author)
Harvard Business Review Press
Will be published approx. on 1. November 1996
Book
Hardback
343 pages
978-0-87584-650-7 (ISBN)
Description
Gary Pisano argues that the development of distinctive and superior process technologies is a key source of competitive advantage. In a multi-year study of international pharmaceutical firms (with references to a variety of other industries), he challenges the widely held product/process life cycle view of competition, which suggests that industries tend to emphasize either product innovation or process innovation. He also offers a set of recommendations for the practices and approaches that can be used to unlock the potential of process development. In doing so, he provides a window into the more general phenomenon of how organizations create, select, and implement new capabilities.
More details
Language
English
Place of publication
United States
Target group
Professional and scholarly
Product notice
Cloth over boards
Illustrations
Illustrations
Dimensions
Height: 241 mm
Width: 162 mm
Thickness: 33 mm
Weight
712 gr
ISBN-13
978-0-87584-650-7 (9780875846507)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Person
Gary P. Pisano is the Harry E. Figgle Jr. Professor of Business Administration and Head of the Technology and Operations Management unit at Harvard Business School.
Content
Introduction - process development as a competitive weapon; framework for process development; the evolving nature of competition in pharmaceuticals; the strategic level of process development capabilities; the anatomy of process development; the determinants of performance-development lead time and cost; Quality in the development process- leveraging knowledge in chemical synthesis; learning across projects in biotechnology; the concepts in action - case studies; conclusion and implications - beyond pharmeceuticals.